共 197 条
- [1] Wang L(2022)Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019 Front Public Health 10 811044-5
- [2] Lu B(2018)The incidence of prostate cancer in Iran: a systematic review and meta-analysis Prostate Int 6 41-65
- [3] He M(2022)Targeted approaches in Metastatic Castration-resistant prostate Cancer Which Data? Cancers 14 4189-23
- [4] Wang Y(2022)Androgen deprivation therapy in high-risk localized and locally advanced prostate cancer Cancers 14 1803-22
- [5] Wang Z(2022)Sequencing of systemic therapies in the management of advanced prostate Cancer in India: a Delphi-based Consensus Oncol Therapy 10 143-2005
- [6] Du L(2013)Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 213-97
- [7] Hassanipour S(2010)Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 411-80
- [8] Fathalipour M(2011)Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 1995-19
- [9] Salehiniya H(2012)Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 1187-40
- [10] Mosillo C(2016)Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide Clin Pharmacokinet 55 1369-78